An implicit price of a DALY for use in a cost-benefit analysis of ARVs

Robert Brent

Applied Economics, 2011, vol. 43, issue 11, 1413-1421

Abstract: This article uses the revealed preference approach to estimate the price for a Disability Adjusted Life Year (DALY) implied by grant decisions by the Global Fund for AIDS, tuberculosis (TB) and malaria (GFATM). A cost-benefit criterion is used that requires the DALY price exceed the cost-effectiveness ratio. The estimated price was $6300 for a DALY saved from any disease, but it was $11 900 from a DALY saved specifically from HIV/AIDS. Estimates of the cost-effectiveness ratios of Antiretroviral Drug Therapies (ARVs) in the literature were examined. At the DALY prices implicit by GFATM decisions, ARVs would be socially worthwhile.

Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (10)

Downloads: (external link)
http://www.tandfonline.com/doi/abs/10.1080/00036840802600475 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:applec:v:43:y:2011:i:11:p:1413-1421

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/RAEC20

DOI: 10.1080/00036840802600475

Access Statistics for this article

Applied Economics is currently edited by Anita Phillips

More articles in Applied Economics from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().